Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN HYDROCHLORIDE versus LINCOMYCIN HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN HYDROCHLORIDE versus LINCOMYCIN HCL.
CLEOCIN HYDROCHLORIDE vs LINCOMYCIN HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin hydrochloride is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, thereby interfering with peptide bond formation and chain elongation.
Lincomycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, inhibiting peptide bond formation and translocation.
150-450 mg orally every 6 hours (oral capsules). Maximum dose: 1.8 g/day.
600 mg IM every 12-24 hours or 600 mg IV every 8-12 hours, up to 8 g/day for severe infections.
None Documented
None Documented
Terminal elimination half-life is approximately 2.4 to 3.0 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life may be prolonged up to 8.5 hours. No significant change in renal impairment.
4-5 hours (prolonged in renal impairment, up to 10 hours in anuria; no significant change in hepatic disease).
Approximately 10% of the active drug is excreted in urine as unchanged clindamycin; about 3.6% in feces; remainder is metabolized primarily in liver. Renal excretion accounts for ~10% of elimination, biliary/fecal route accounts for ~90% including metabolites.
Renal (approximately 40% unchanged in urine) and biliary/fecal (approximately 50% as active drug and metabolites).
Category C
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic